Can-Fite BioPharma Ltd.(CANF)Earnings, Financials & Key Ratios
CANF•AMEX
$3.49
$25M mkt cap·Price updated May 6, 2026
AboutCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Show more
- Revenue$674K-9.3%
- EBITDA-$8M+0.7%
- Net Income-$8M-3.2%
- EPS (Diluted)-1.08+40.0%
- Gross Margin100%
- EBITDA Margin-1205.19%-9.5%
- Operating Margin-1206.23%-9.4%
- Net Margin-1169.14%-13.8%
- ROE-134.94%+5.3%
- ROIC-448.35%-29.9%
- Debt/Equity0.02+198.6%
- Interest Coverage-580.71+0.8%
CANF Key Insights
Can-Fite BioPharma Ltd. (CANF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 99 (top 1%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 19.8% over 5 years
- ✗Shares diluted 70.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CANF Price & Volume
Can-Fite BioPharma Ltd. (CANF) stock price & volume — 10-year historical chart
Loading chart...
CANF Growth Metrics
Can-Fite BioPharma Ltd. (CANF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-19.81%
3 Years-7.55%
TTM-16.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-19.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.17%
Return on Capital
10 Years-119.67%
5 Years-123.38%
3 Years-100.78%
Last Year-108.13%
CANF Peer Comparison
Can-Fite BioPharma Ltd. (CANF) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.63B | 21.48 | 15.79 | 31.85% | 24.94% | 28.47% | 4.33% | 0.07 |
 INVA | 1.68B | 22.52 | 6.82 | 18.52% | 65.38% | 23.12% | 11.65% | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | 4.91% | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
 AMGN | 178.7B | 331.11 | 23.27 | 9.92% | 20.95% | 89.41% | 4.53% | 6.31 |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 5.45% | 0.09 |
Compare CANF vs Peers
Can-Fite BioPharma Ltd. (CANF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CANF Income Statement
Can-Fite BioPharma Ltd. (CANF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 169.5K | 844.75K | 3.82M | 2.03M | 763K | 853K | 810K | 743K | 674K | 560K |
| Revenue Growth % | 2.9% | 398.38% | 352.21% | -46.81% | -62.45% | 11.8% | -5.04% | -8.27% | -9.29% | -16.04% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 169.5K▲ 0% | 844.75K▲ 398.4% | 3.82M▲ 352.2% | 2.03M▼ 46.8% | 763K▼ 62.5% | 853K▲ 11.8% | 810K▼ 5.0% | 743K▼ 8.3% | 674K▼ 9.3% | 560K▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | 2.9% | 398.38% | 352.21% | -46.81% | -62.45% | 11.8% | -5.04% | -8.27% | -9.29% | - |
| Operating Expenses | 8.8M | 8.22M | 9.23M | 14.04M | 14.9M | 13.7M | 10.91M | 8.94M | 8.8M | 9.49M |
| OpEx % of Revenue | 5193.72% | 973.13% | 241.73% | 690.9% | 1953.08% | 1605.51% | 1346.42% | 1202.96% | 1306.23% | - |
| Selling, General & Admin | 2.7M | 2.95M | 3.16M | 3.06M | 2.95M | 3.85M | 3.14M | 2.96M | 3.05M | 3.59M |
| SG&A % of Revenue | 1590.8% | 349.08% | 82.7% | 150.74% | 386.76% | 450.76% | 388.02% | 397.71% | 452.08% | - |
| Research & Development | 6.08M | 5.27M | 6.08M | 10.98M | 11.95M | 9.85M | 7.76M | 5.98M | 5.76M | 5.91M |
| R&D % of Revenue | 3585.9% | 624.05% | 159.03% | 540.16% | 1566.32% | 1154.75% | 958.4% | 805.25% | 854.15% | - |
| Other Operating Expenses | 28.86K | 31.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.63M▲ 0% | -7.38M▲ 14.6% | -5.41M▲ 26.6% | -12.01M▼ 121.8% | -14.14M▼ 17.8% | -12.84M▲ 9.2% | -10.1M▲ 21.4% | -8.2M▲ 18.8% | -8.13M▲ 0.8% | -8.93M▲ 0% |
| Operating Margin % | -5093.72% | -873.13% | -141.73% | -590.9% | -1853.08% | -1505.51% | -1246.42% | -1102.96% | -1206.23% | -1595.36% |
| Operating Income Growth % | -34.59% | 14.57% | 26.6% | -121.78% | -17.76% | 9.17% | 21.38% | 18.83% | 0.79% | - |
| EBITDA | -8.62M | -7.36M | -5.4M | -11.99M | -14.13M | -12.83M | -10.08M | -8.18M | -8.12M | -8.91M |
| EBITDA Margin % | -5082.83% | -870.78% | -141.36% | -590.21% | -1851.51% | -1503.87% | -1244.69% | -1100.94% | -1205.19% | -1590.18% |
| EBITDA Growth % | -34.64% | 14.62% | 26.59% | -122.09% | -17.79% | 9.2% | 21.41% | 18.87% | 0.7% | -14.39% |
| D&A (Non-Cash Add-back) | 18.46K | 19.85K | 14K | 14K | 12K | 14K | 14K | 15K | 7K | 29K |
| EBIT | -8.36M | -6.4M | -6.14M | -12.01M | -14.14M | -12.84M | -10.1M | -8.2M | -8.13M | -8.93M |
| Net Interest Income | 61.74K | 41K | 33K | -376K | -343K | 6K | 206K | 492K | 277K | 176K |
| Interest Income | 89.09K | 69K | 51K | 72K | 44K | 24K | 222K | 506K | 291K | 176K |
| Interest Expense | 27.35K | 28K | 18K | 448K | 387K | 18K | 16K | 14K | 14K | 0 |
| Other Income/Expense | 269.86K | 781K | -1.15M | -618K | -304K | 227K | -77K | 561K | 250K | 135K |
| Pretax Income | -6.99M▲ 0% | -4.95M▲ 29.2% | -6.57M▼ 32.6% | -12.63M▼ 92.2% | -14.44M▼ 14.4% | -12.62M▲ 12.7% | -10.17M▲ 19.4% | -7.63M▲ 25.0% | -7.88M▼ 3.2% | -8.8M▲ 0% |
| Pretax Margin % | -4125.31% | -586.07% | -171.91% | -621.31% | -1892.92% | -1478.9% | -1255.93% | -1027.46% | -1169.14% | -1571.07% |
| Income Tax | 29.12K | 29.92K | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.42% | -0.6% | -0.06% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.9M▲ 0% | -4.97M▲ 28.0% | -6.57M▼ 32.2% | -12.63M▼ 92.1% | -14.44M▼ 14.4% | -12.6M▲ 12.8% | -10.17M▲ 19.2% | -7.63M▲ 25.0% | -7.88M▼ 3.2% | -8.8M▲ 0% |
| Net Margin % | -4069.33% | -588.18% | -172.02% | -621.31% | -1892.92% | -1476.55% | -1255.93% | -1027.46% | -1169.14% | -1571.07% |
| Net Income Growth % | -43.79% | 27.96% | -32.25% | -92.13% | -14.4% | 12.8% | 19.23% | 24.96% | -3.22% | -19.38% |
| Net Income (Continuing) | -8.39M | -6.43M | -6.57M | -12.63M | -14.44M | -12.62M | -10.17M | -7.63M | -7.88M | -8.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 8.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -90.00▲ 0% | -57.00▲ 36.7% | -51.00▲ 10.5% | -45.00▲ 11.8% | -12.69▲ 71.8% | -8.25▲ 35.0% | -3.75▲ 54.5% | -1.80▲ 52.0% | -1.08▲ 40.0% | -0.77▲ 0% |
| EPS Growth % | -11.11% | 36.67% | 10.53% | 11.76% | 71.8% | 34.99% | 54.55% | 52% | 40% | 36.17% |
| EPS (Basic) | -90.00 | -57.00 | -51.00 | -45.00 | -12.69 | -9.00 | -3.75 | -1.80 | -1.08 | - |
| Diluted Shares Outstanding | 92.31K | 108.42K | 129.67K | 286.37K | 1.19M | 1.84M | 2.72M | 4.26M | 7.25M | 11.37M |
| Basic Shares Outstanding | 92.31K | 108.42K | 129.67K | 286.37K | 1.14M | 1.53M | 2.72M | 4.26M | 7.25M | 11.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CANF Balance Sheet
Can-Fite BioPharma Ltd. (CANF) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.1M | 6.87M | 7.9M | 7.14M | 9.4M | 20.07M | 9.16M | 9.91M | 8.98M | 7.62M |
| Cash & Short-Term Investments | 8.11M | 3.5M | 3.89M | 2.76M | 8.34M | 19.14M | 7.98M | 8.92M | 7.89M | 6.46M |
| Cash Only | 8.11M | 3.5M | 3.62M | 2.7M | 8.27M | 4.39M | 2.98M | 4.28M | 4.83M | 6.45M |
| Short-Term Investments | 0 | 0 | 273K | 64K | 75K | 14.75M | 5M | 4.64M | 3.06M | 2K |
| Accounts Receivable | 21.84K | 0 | 0 | 637K | 18K | 48K | 47K | 78K | 77K | 0 |
| Days Sales Outstanding | 47.02 | - | - | 114.42 | 8.61 | 20.54 | 21.18 | 38.32 | 41.7 | 12.55 |
| Inventory | 0 | -3.3M | 0 | -715K | 0 | -48K | -39K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 41K | 729K | 0 | 48K | 47K | 0 | 1.02M | 0 |
| Total Non-Current Assets | 62.91K | 965.88K | 49K | 1.03M | 123K | 185K | 126K | 81K | 138K | 96K |
| Property, Plant & Equipment | 53.29K | 46.03K | 47K | 118K | 123K | 185K | 126K | 81K | 138K | 96K |
| Fixed Asset Turnover | 3.18x | 18.35x | 81.28x | 17.22x | 6.20x | 4.61x | 6.43x | 9.17x | 4.88x | 4.79x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 914.66K | 0 | 0 | 0 | 0 | 8K | 0 | 0 | 0 |
| Other Non-Current Assets | 9.62K | 5.18K | 2K | 912K | 0 | 0 | -8K | 0 | 0 | 0 |
| Total Assets | 10.17M▲ 0% | 7.83M▼ 23.0% | 7.95M▲ 1.5% | 8.17M▲ 2.8% | 9.52M▲ 16.5% | 20.25M▲ 112.7% | 9.28M▼ 54.2% | 9.99M▲ 7.6% | 9.12M▼ 8.7% | 7.72M▲ 0% |
| Asset Turnover | 0.02x | 0.11x | 0.48x | 0.25x | 0.08x | 0.04x | 0.09x | 0.07x | 0.07x | 0.07x |
| Asset Growth % | -42.24% | -22.96% | 1.53% | 2.79% | 16.5% | 112.67% | -54.16% | 7.61% | -8.7% | 51.49% |
| Total Current Liabilities | 2.5M | 1.8M | 3.12M | 3.27M | 1.27M | 2.73M | 2.5M | 2.02M | 2.05M | 2.12M |
| Accounts Payable | 1.25M | 427K | 1.07M | 2.16M | 561K | 954K | 896K | 427K | 618K | 1.15M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 43K | 53K | 48K | 27K | 53K | 0 |
| Deferred Revenue (Current) | 321.58K | 373.75K | 926K | 469K | 334K | 818K | 783K | 622K | 405K | 810K |
| Other Current Liabilities | 669K | 268.39K | 149K | 165K | 53K | 550K | 444K | 667K | 622K | 0 |
| Current Ratio | 4.04x | 3.82x | 2.53x | 2.18x | 7.41x | 7.35x | 3.66x | 4.90x | 4.38x | 4.38x |
| Quick Ratio | 4.04x | 5.66x | 2.53x | 2.40x | 7.41x | 7.37x | 3.68x | 4.90x | 4.38x | 4.38x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 12.55 |
| Total Non-Current Liabilities | 3.79M | 2.98M | 1.82M | 2.46M | 2.18M | 3.14M | 2.31M | 1.73M | 1.63M | 1.42M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 39K | 24K | 71K | 14K | 13K | 51K | 168K |
| Deferred Tax Liabilities | 0 | 0 | 0 | -2.42M | -2.16M | -3.07M | -2.29M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.62M | 2.14M | 0 | 1.57M | 2.16M | 3.07M | 2.29M | 0 | 0 | 2.96M |
| Total Liabilities | 6.29M | 4.78M | 4.94M | 5.73M | 3.45M | 5.87M | 4.81M | 3.75M | 3.68M | 3.54M |
| Total Debt | 0 | 0 | 0 | 75K | 67K | 124K | 62K | 40K | 104K | 90K |
| Net Debt | -8.11M | -3.5M | -3.62M | -2.62M | -8.2M | -4.27M | -2.92M | -4.24M | -4.72M | -6.36M |
| Debt / Equity | - | - | - | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.71x |
| Interest Coverage | -315.66x | -263.42x | -300.78x | -26.80x | -36.53x | -713.44x | -631.04x | -585.36x | -580.71x | - |
| Total Equity | 3.87M▲ 0% | 3.05M▼ 21.2% | 3.02M▼ 1.3% | 2.44M▼ 19.0% | 6.07M▲ 148.7% | 14.38M▲ 136.8% | 4.47M▼ 68.9% | 6.24M▲ 39.6% | 5.44M▼ 12.9% | 4.18M▲ 0% |
| Equity Growth % | -62.91% | -21.17% | -1.27% | -19% | 148.73% | 136.78% | -68.91% | 39.6% | -12.93% | 128.47% |
| Book Value per Share | 41.97 | 28.17 | 23.25 | 8.53 | 5.08 | 7.80 | 1.64 | 1.47 | 0.75 | 0.37 |
| Total Shareholders' Equity | 3.87M | 3.05M | 3.02M | 2.44M | 6.07M | 14.38M | 4.47M | 6.24M | 5.44M | 4.18M |
| Common Stock | 1.83M | 2.39M | 2.63M | 8.22M | 33.04M | 60.65M | 0 | 0 | 0 | 0 |
| Retained Earnings | -90.98M | -105.66M | -100.62M | -110.31M | -125.47M | -140.67M | -150.85M | -158.48M | -166.36M | -171.24M |
| Treasury Stock | -943.17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 5.08M | 6.28M | 6.93M | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M |
| Minority Interest | 8.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CANF Cash Flow Statement
Can-Fite BioPharma Ltd. (CANF) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.93M | -9.52M | -4.16M | -10.83M | -12.06M | -9.86M | -10.8M | -8.44M | -7.64M | -7.64M |
| Operating CF Margin % | -5266.88% | -1127.35% | -108.77% | -533.17% | -1581% | -1155.69% | -1333.46% | -1135.94% | -1133.09% | - |
| Operating CF Growth % | -91.91% | -6.67% | 56.37% | -160.75% | -11.34% | 18.28% | -9.57% | 21.86% | 9.51% | -1830.74% |
| Net Income | -7.02M | -4.98M | -6.57M | -12.63M | -14.44M | -12.62M | -10.17M | -7.63M | -7.88M | -8.8M |
| Depreciation & Amortization | 18.46K | 19.85K | 14K | 14K | 12K | 14K | 14K | 15K | 7K | 29K |
| Stock-Based Compensation | 309K | 195.07K | 535K | 385K | 355K | 466K | 263K | 261K | 362K | 420K |
| Deferred Taxes | 0 | 278.51K | 0 | 212K | 11K | -94K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.47M | -2.59M | 733K | -5K | 1K | -59K | 396K | -139K | 141K | 19K |
| Working Capital Changes | -449.49K | -2.45M | 1.13M | 1.19M | 2M | 2.43M | -1.3M | -943K | -267K | -22K |
| Change in Receivables | -1.37M | -1.16M | -853K | 270K | 2.73M | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 125K | -316K | 1.27M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 591.95K | -964.15K | 644K | 1.08M | -1.59M | 393K | -58K | -469K | 191K | 0 |
| Cash from Investing | -10.4K | -29.64K | -33K | -253K | -26K | -14.51M | 9.5M | 498K | 1.5M | -2K |
| Capital Expenditures | -10.4K | -6.91K | -33K | -3K | -26K | -11K | -9K | -2K | -5K | -2K |
| CapEx % of Revenue | 6.13% | 0.82% | 0.86% | 0.15% | 3.41% | 1.29% | 1.11% | 0.27% | 0.74% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -22K | 0 | -250K | 0 | 0 | 9.51M | 500K | 1.5M | 0 |
| Cash from Financing | 0 | 4.88M | 4.39M | 10.17M | 17.68M | 20.46M | 0 | 9.14M | 6.71M | 10.08M |
| Debt Issued (Net) | 0 | 0 | 0 | -34K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 34K | 0 | 0 | 0 | 0 | 0 | 10.08M |
| Net Change in Cash | -9.05M▲ 0% | -5.48M▲ 39.5% | 110K▲ 102.0% | -918K▼ 934.5% | 5.57M▲ 706.9% | -3.88M▼ 169.6% | -1.41M▲ 63.6% | 1.3M▲ 192.1% | 547K▼ 57.9% | -4.72M▲ 0% |
| Free Cash Flow | -8.94M▲ 0% | -9.53M▼ 6.6% | -4.19M▲ 56.1% | -10.84M▼ 158.8% | -12.09M▼ 11.6% | -9.87M▲ 18.4% | -10.81M▼ 9.5% | -8.44M▲ 21.9% | -7.64M▲ 9.5% | -8.36M▲ 0% |
| FCF Margin % | -5273.02% | -1128.17% | -109.63% | -533.32% | -1584.4% | -1156.98% | -1334.57% | -1136.2% | -1133.83% | -1491.96% |
| FCF Growth % | -90.28% | -6.63% | 56.06% | -158.76% | -11.55% | 18.36% | -9.53% | 21.91% | 9.48% | -102.06% |
| FCF per Share | -96.83 | -87.90 | -32.30 | -37.84 | -10.12 | -5.35 | -3.98 | -1.98 | -1.05 | -1.05 |
| FCF Conversion (FCF/Net Income) | 1.29x | 1.92x | 0.63x | 0.86x | 0.84x | 0.78x | 1.06x | 1.11x | 0.97x | 0.95x |
| Interest Paid | 0 | 23K | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 29K | 29K | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CANF Key Ratios
Can-Fite BioPharma Ltd. (CANF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -96.34% | -143.44% | -216.55% | -462.71% | -339.2% | -123.14% | -107.91% | -142.49% | -134.94% | -210.28% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -241.12% | -129.75% | -345.2% | -448.35% | -448.35% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -4069.33% | -588.18% | -172.02% | -621.31% | -1892.92% | -1476.55% | -1255.93% | -1027.46% | -1169.14% | -1571.07% |
| Debt / Equity | - | - | - | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.02x |
| Interest Coverage | -315.66x | -263.42x | -300.78x | -26.80x | -36.53x | -713.44x | -631.04x | -585.36x | -580.71x | - |
| FCF Conversion | 1.29x | 1.92x | 0.63x | 0.86x | 0.84x | 0.78x | 1.06x | 1.11x | 0.97x | 0.95x |
| Revenue Growth | 2.9% | 398.38% | 352.21% | -46.81% | -62.45% | 11.8% | -5.04% | -8.27% | -9.29% | -16.04% |
CANF Frequently Asked Questions
Can-Fite BioPharma Ltd. (CANF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Can-Fite BioPharma Ltd. (CANF) reported $0.6M in revenue for fiscal year 2024. This represents a 19% increase from $0.5M in 2011.
Can-Fite BioPharma Ltd. (CANF) saw revenue decline by 9.3% over the past year.
Can-Fite BioPharma Ltd. (CANF) reported a net loss of $8.8M for fiscal year 2024.
Dividend & Returns
Can-Fite BioPharma Ltd. (CANF) has a return on equity (ROE) of -134.9%. Negative ROE indicates the company is unprofitable.
Can-Fite BioPharma Ltd. (CANF) had negative free cash flow of $8.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More CANF
Can-Fite BioPharma Ltd. (CANF) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates